Trevi Therapeutics, Inc.
TRVINext catalyst
NAL ER
Refractory Chronic Cough
Get an email about TRVI's next catalysts
Track Trevi Therapeutics (TRVI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (earnings, Phase 2 readout).See the timeline
3 upcoming, 0 past
TRVI Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.13 | FQ end Sep/2026 | Call: amc
NAL ER Phase 3 Est. Readout (OCEAN-2)
Estimated primary completion for NAL ER trial (NCT07868419) in Idiopathic Pulmonary Fibrosis. Topline data typically follows completion by weeks to months.
SourceNAL ER Phase 2 Est. Readout (LAKE)
Estimated primary completion for NAL ER trial (NCT07671924) in Refractory Chronic Cough. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Nalbuphine ER Tablets
Prurigo Nodularis
NAL ER
Refractory Chronic Cough
nalbuphine HCl ER
Uremic Pruritus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Nalbuphine ER Tablets | Phase 3 | Prurigo Nodularis | - | - |
NAL ER | Phase 3 | Refractory Chronic Cough | - | - |
nalbuphine HCl ER | Phase 3 | Uremic Pruritus | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Trevi Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Trevi Therapeutics, Inc.'s (TRVI) pipeline across Phase 3. Its lead program is NAL ER (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Trevi Therapeutics, Inc.'s next FDA catalyst?→
Trevi Therapeutics, Inc.'s (TRVI) next tracked catalyst is a Phase 3 readout expected August 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TRVI biotech catalysts?→
Add TRVI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Trevi Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.